Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib

Overview of attention for article published in Annals of Hematology, March 2017

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (68th percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

So far, Altmetric has seen 6 X posts from 5 X users, with an upper bound of 20,781 followers.

RT @SCTNB: Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib. - PubMed - NCBI https://t.co/R0c…

RT @SCTNB: Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib. - PubMed - NCBI https://t.co/R0c…

RT @SCTNB: Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib. - PubMed - NCBI https://t.co/R0c…

RT @SCTNB: Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib. - PubMed - NCBI https://t.co/R0c…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.